HIV-1 Infected Lymphoid Organs Upregulate Expression and Release of the Cleaved Form of uPAR That Modulates Chemotaxis and Virus Expression

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Nebuloni, Manuela ^a   Zawada, Lidia ^a   Ferri, Angelita ^a   Tosoni, Antonella ^a   Zerbi, Pietro ^a   Resnati, Massimo ^b   Poli, Guido ^b,c   Genovese, Luca ^b   Alfano, Massimo ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; INTEGRIN; MONOCYTE CHEMOTACTIC PROTEIN 1; UROKINASE;

ADOLESCENT; ADULT; ARTICLE; BINDING AFFINITY; CELL COUNT; CELL MIGRATION; CELLULAR DISTRIBUTION; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FOLLICULAR DENDRITIC CELL; HISTOCHEMISTRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOREACTIVITY; LYMPHOID ORGAN; MACROPHAGE; MALE; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; TONSIL; UPREGULATION; VIRUS REPLICATION; VIRUS STRAIN;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CHEMOTAXIS; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LYMPH NODES; LYMPHOID TISSUE; MALE; MIDDLE AGED; PALATINE TONSIL; PROTEOLYSIS; RECEPTORS, CCR2; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 84880769072     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070606     Document Type: Article

References (77)

1. Douek DC, Picker LJ, Koup RA, (2003) T cell dynamics in HIV-1 infection. Annu Rev Immunol 21: 265-304.
2. Silvestri G, Sodora DL, Koup RA, Paiardini M, O'Neil SP, et al. (2003) Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 18: 441-452.
3. Fang CT, Chang YY, Hsu HM, Twu SJ, Chen KT, et al. (2007) Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM 100: 97-105.
4. Nixon DE, Landay AL, (2010) Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS 5: 498-503.
5. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15: 893-900.
6. Keele BF, Tazi L, Gartner S, Liu Y, Burgon TB, et al. (2008) Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J Virol 82: 5548-5561.
7. Heath SL, Tew JG, Szakal AK, Burton GF, (1995) Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377: 740-744.
8. Tenner-Racz K, von Stemm AM, Guhlk B, Schmitz J, Racz P, (1994) Are follicular dendritic cells, macrophages and interdigitating cells of the lymphoid tissue productively infected by HIV? Res Virol 145: 177-182.
9. Haase AT, (1999) Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol 17: 625-656.
10. Gratton S, Cheynier R, Dumaurier MJ, Oksenhendler E, Wain-Hobson S, (2000) Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. Proc Natl Acad Sci U S A 97: 14566-14571.
11. Lindqvist M, van Lunzen J, Soghoian DZ, Kuhl BD, Ranasinghe S, et al. (2012) Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest 122: 3271-3280.
12. Pantaleo G, Cohen OJ, Schacker T, Vaccarezza M, Graziosi C, et al. (1998) Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nat Med 4: 341-345.
13. Perrin L, Yerly S, Marchal F, Schockmel GA, Hirschel B, et al. (1998) Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy. J Infect Dis 177: 1497-1501.
14. Cohen J, (2011) HIV/AIDS research. Tissue says blood is misleading, confusing HIV cure efforts. Science 334: 1614.
15. Schacker T, Stevenson M, Fletcher C, (2011) Anatomic HIV reservoir. Paper presented at the 5th International Worshop on HIV Persistence, Reservoirs and Eradication Strategies. St Maarten, West Indies: December 6-9, 2011. Global Antiviral Journal 2011(suppl 2): 28-29.
16. Blasi F, Sidenius N, (2010) The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 584: 1923-1930.
17. Small-Howard AL, Harris H, (2010) Advantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patients. J Immunoassay Immunochem 31: 131-147.
18. Sidenius N, Sier CF, Blasi F, (2000) Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett 475: 52-56.
19. Thuno M, Macho B, Eugen-Olsen J, (2009) suPAR: the molecular crystal ball. Dis Markers 27: 157-172.
20. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, et al. (2000) Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96: 4091-4095.
21. Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB, (2008) Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J Med Virol 80: 209-216.
22. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, et al. (2005) High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 39: 23-31.
23. Ostrowski SR, Katzenstein TL, Pedersen M, Hoyer-Hansen G, Gerstoft J, et al. (2006) Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy. Scand J Immunol 63: 478-486.
24. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, et al. (2003) T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 187: 1534-1543.
25. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5: e203.
26. Porter BO, Ouedraogo GL, Hodge JN, Smith MA, Pau A,et al. d-Dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS. Clin Immunol 136: 42-50.
27. Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, et al. (2011) Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 203: 1637-1646.
28. Alfano M, Sidenius N, Panzeri B, Blasi F, Poli G, (2002) Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication. Proc Natl Acad Sci U S A 99: 8862-8867.
29. Wada M, Wada NA, Shirono H, Taniguchi K, Tsuchie H, et al. (2001) Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication. Biochem Biophys Res Commun 284: 346-351.
30. Elia C, Cassol E, Sidenius N, Blasi F, Castagna A, et al. (2007) Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion. J Leukoc Biol 82: 1212-1220.
31. Graziano F, Elia C, Laudanna C, Poli G, Alfano M, (2011) Urokinase Plasminogen Activator Inhibits HIV Virion Release from Macrophage-Differentiated Chronically Infected Cells via Activation of RhoA and PKCepsilon. PLoS ONE 6: e23674.
32. Alfano M, Mariani SA, Elia C, Pardi R, Blasi F, et al. (2009) Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells. Blood 113: 1699-1709.
33. Cinque P, Vago L, Mengozzi M, Torri V, Ceresa D, et al. (1998) Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 12: 1327-1332.
34. Ragin AB, Wu Y, Ochs R, Scheidegger R, Cohen BA, et al. (2010) Biomarkers of neurological status in HIV infection: a 3-year study. Proteomics Clin Appl 4: 295-303.
35. Mengozzi M, De Filippi C, Transidico P, Biswas P, Cota M, et al. (1999) Human immunodeficiency virus replication induces monocyte chemotactic protein-1 in human macrophages and U937 promonocytic cells. Blood 93: 1851-1857.
36. Rusnati M, Coltrini D, Campioni D, Tanghetti E, Corallini A, et al. (1997) Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice. Aids 11: 727-736.
37. Speth C, Pichler I, Stockl G, Mair M, Dierich MP, (1998) Urokinase plasminogen activator receptor (uPAR; CD87) expression on monocytic cells and T cells is modulated by HIV-1 infection. Immunobiology 199: 152-162.
38. Ansari AW, Heiken H, Meyer-Olson D, Schmidt RE CCL2: A potential prognostic marker and target of anti-inflammatory strategy in HIV/AIDS pathogenesis. Eur J Immunol 41: 3412-3418.
39. Nalla AK, Gogineni VR, Gupta R, Dinh DH, Rao JS Suppression of uPA and uPAR blocks radiation-induced MCP-1 mediated recruitment of endothelial cells in meningioma. Cell Signal 23: 1299-1310.
40. Cross AK, Woodroofe MN, (1999) Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro. Glia 28: 183-189.
41. Montuori N, Ragno P, (2009) Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPAR. Front Biosci 14: 2494-2503.
42. Alfano M, Grivel JC, Ghezzi S, Corti D, Trimarchi M, et al. (2005) Pertussis toxin B-oligomer dissociates T cell activation and HIV replication in CD4 T cells released from infected lymphoid tissue. Aids 19: 1007-1014.
43. Grivel JC, Margolis L, (2009) Use of human tissue explants to study human infectious agents. Nat Protoc 4: 256-269.
44. Nebuloni M, Cinque P, Sidenius N, Ferri A, Lauri E, et al. (2009) Expression of the urokinase plasminogen activator receptor (uPAR) and its ligand (uPA) in brain tissues of human immunodeficiency virus patients with opportunistic cerebral diseases. J Neurovirol 15: 99-107.
45. Sidenius N, Nebuloni M, Sala S, Zerbi P, Price RW, et al. (2004) Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease. J Neuroimmunol 157: 133-139.
46. Abdel-Latif L, Murray BK, Renberg RL, O'Neill KL, Porter H, et al. (2006) Cell death in bovine parvovirus-infected embryonic bovine tracheal cells is mediated by necrosis rather than apoptosis. J Gen Virol 87: 2539-2548.
47. Resnati M, Pallavicini I, Daverio R, Sidenius N, Bonini P, et al. (2006) Specific immunofluorimetric assay detecting the chemotactic epitope of the urokinase receptor (uPAR). J Immunol Methods 308: 192-202.
48. Folks T, Powell DM, Lightfoote MM, Benn S, Martin MA, et al. (1986) Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. Science 231: 600-602.
49. Alfano M, Rizzi C, Poli G, Biswas P (2007) HIV-1 Infection of promonocytic U937 and U1 cell lines. Clonal distribution of innate restriction factors. In: Herbein G, editor. HIV and the Macrophage. Kerala, India: Transworld Research Network. 89-113.
50. Cassol E, Alfano M, Biswas P, Poli G, (2006) Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence. J Leukoc Biol 80: 1018-1030.
51. Palmisano I, Della Chiara G, D'Ambrosio RL, Huichalaf C, Brambilla P, et al. (2012) Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proc Natl Acad Sci U S A 109: E2284-2293.
52. Alfano M, Vallanti G, Biswas P, Bovolenta C, Vicenzi E, et al. (2001) The binding subunit of pertussis toxin inhibits HIV replication in human macrophages and virus expression in chronically infected promonocytic U1 cells. J Immunol 166: 1863-1870.
53. Graziosi C, Pantaleo G, Demarest JF, Cohen OJ, Vaccarezza M, et al. (1993) HIV-1 infection in the lymphoid organs. AIDS 7Suppl 2: S53-58.
54. Eden G, Archinti M, Furlan F, Murphy R, Degryse B, (2011) The urokinase receptor interactome. Curr Pharm Des 17: 1874-1889.
55. Selleri C, Montuori N, Ricci P, Visconte V, Carriero MV, et al. (2005) Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood 105: 2198-2205.
56. Grivel JC, Elliott J, Lisco A, Biancotto A, Condack C, et al. (2007) HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1. Aids 21: 1263-1272.
57. Biancotto A, Grivel JC, Iglehart SJ, Vanpouille C, Lisco A, et al. (2007) Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood 109: 4272-4279.
58. Nykjaer A, Moller B, Todd RF, 3rd, Christensen T, Andreasen PA, et al (1994) Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol 152: 505-516.
59. Cinque P, Nebuloni M, Santovito ML, Price RW, Gisslen M, et al. (2004) The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. Ann Neurol 55: 687-694.
60. Binder BR, Mihaly J, Prager GW, (2007) uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 97: 336-342.
61. Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, et al. (2004) Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 35: 337-342.
62. Ostrowski SR, Haastrup E., Langkilde A., Ullum H., Eugen-Olsen J. (2010) The uPA/uPAR system and suPAR in HIV infection. In: Alfano M, editor. Soluble factors mediating innate immunity responses to HIV infection: Bentham Science Publisher Ltd. 81-101.
63. Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS, (2002) D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest 121: 1262-1268.
64. Lomholt AF, Christensen IJ, Hoyer-Hansen G, Nielsen HJ Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol 49: 805-811.
65. Wei C, El Hindi S, Li J, Fornoni A, Goes N, et al. (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952-960.
66. Kaufman L, Collins SE, Klotman PE, (2010) The pathogenesis of HIV-associated nephropathy. Adv Chronic Kidney Dis 17: 36-43.
67. Alfano M, Poli G, (2005) Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. Mol Immunol 42: 161-182.
68. Gyetko MR, Sud S, Kendall T, Fuller JA, Newstead MW, et al. (2000) Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol 165: 1513-1519.
69. Mellado M, Rodriguez-Frade JM, Vila-Coro AJ, Fernandez S, Martin de Ana A, et al. (2001) Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J 20: 2497-2507.
70. Li BQ, Wetzel MA, Mikovits JA, Henderson EE, Rogers TJ, et al. (2001) The synthetic peptide WKYMVm attenuates the function of the chemokine receptors CCR5 and CXCR4 through activation of formyl peptide receptor-like 1. Blood 97: 2941-2947.
71. Shimizu N, Tanaka A, Mori T, Ohtsuki T, Hoque A, et al. (2008) A formylpeptide receptor, FPRL1, acts as an efficient coreceptor for primary isolates of human immunodeficiency virus. Retrovirology 5: 52.
72. Nedellec R, Coetzer M, Shimizu N, Hoshino H, Polonis VR, et al. (2009) Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype. J Virol 83: 8353-8363.
73. Gross E, Amella CA, Pompucci L, Franchin G, Sherry B, et al. (2003) Macrophages and lymphocytes differentially modulate the ability of RANTES to inhibit HIV-1 infection. J Leukoc Biol 74: 781-790.
74. Amella CA, Sherry B, Shepp DH, Schmidtmayerova H, (2005) Macrophage inflammatory protein 1alpha inhibits postentry steps of human immunodeficiency virus type 1 infection via suppression of intracellular cyclic AMP. J Virol 79: 5625-5631.
75. Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, et al. (2012) Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 12: 607-614.
76. Masucci MT, Pedersen N, Blasi F, (1991) A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor. J Biol Chem 266: 8655-8658.
77. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, et al. (1997) A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. Embo J 16: 7279-7286.